UBS Group upgraded the stock rating for Sartorius Stedim Biotech S.A. on August 1, 2026, and MarketBeat reported the average rating.
2 reports, 1 independent
Updated Nov 1
No new developments lately
- Reports
- 2
- Developments
- 2
- Repetition
- 0%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
UBS Group upgraded the stock rating for Sartorius Stedim Biotech S.A. on August 1, 2026, and MarketBeat reported the average rating.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.UBS issued a new stock rating upgrade for Sartorius Stedim Biotech S.A.1 source
UBS upgraded the stock rating for Sartorius Stedim Biotech S.A. on August 1, 2026.1 source
Keep exploring
The entities involved
-
MarketBeat
American personal finance blog
Related events
- MarketBeat reported the stock's average rating as Benchmark and Jefferies reiterated buy ratings for Bright Minds Biosciences Inc.
- MarketBeat reported an average stock rating for Superior Group of Companies.
- MarketBeat reported average stock ratings while Jefferies Financial Group reiterated a buy rating for Sequoia Economic Infrastructure Inc.
- MarketBeat provided stock average ratings while Leerink Partners upgraded and Barclays raised its price objective for Summit Therapeutics.
- MarketBeat reported the stock's average rating while Citigroup reiterated a buy rating and Cantor Fitzgerald restated an overweight rating for Beta Technologies.